Caicun Zhou
Shanghai East Hospital · The East Hospital Affiliated to Tongji University, Shanghai, Shanghai 200120 · Shanghai East Hospital, Yuntailu 1800
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Caicun Zhou as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 15:25 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07912268 · Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung CancerJiangsu Simcere Pharmaceutical Co., Ltd. · not yet recruiting · ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT07868172 · GST101 in Participants With RAS-Mutant Advanced Solid TumorsGenuine Seed Therapeutics (Zhuhai) Co., Ltd. · recruiting · RAS-mutant Advanced Solid Tumors · study chair
- Ph1NCT07582822 · JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLCBiotech Pharmaceutical Co., Ltd. · not yet recruiting · Advanced Solid Tumor · principal investigator
- Ph3NCT07383116 · Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung CancerShanghai Huaota Biopharmaceutical Co., Ltd. · not yet recruiting · Non Squamous Non-small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT07374419 · Atamparib in Patients With Advanced Solid TumorsNerviano Medical Sciences (Shanghai) Ltd. · recruiting · NSCLC Adenocarcinoma, Solid Tumor · principal investigator
- Ph3NCT06928389 · Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung CancerAkeso · recruiting · Non-Small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT06758557 · A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid TumorHuabo Biopharm Co., Ltd. · recruiting · Advanced NSCLC, Advanced Endometrial Cancer · principal investigator
- Ph1/Ph2NCT06631989 · A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung CancerWayshine Biopharm, Inc. · recruiting · EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer · principal investigator
- Ph3NCT06616532 · PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung CancerBiotheus Inc. · active not recruiting · SCLC · principal investigator
- Ph1NCT06612840 · A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid TumorsSichuan Baili Pharmaceutical Co., Ltd. · recruiting · Non-small Cell Lung Cancer, Solid Tumor · principal investigator
- N/ANCT06586801 · The Patient-Reported Outcomes in ALK Positive Advanced NSCLC in ChinaShanghai East Hospital · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph3NCT06564324 · A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer PatientsNuvation Bio Inc. · recruiting · Non Small Cell Lung Cancer · principal investigator
- Ph1NCT06505824 · A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid TumorsBiokin (Shanghai) Biopharmaceutical Co., Ltd. · recruiting · Small Cell Lung Cancer, Neuroendocrine Tumors · principal investigator
- Ph2NCT06498986 · A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerSichuan Baili Pharmaceutical Co., Ltd. · active not recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT06499350 · A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid TumorsFindCure Biosciences (ZhongShan) Co., Ltd. · recruiting · Advanced Malignant Solid Tumors · principal investigator
- Ph1/Ph2NCT06468358 · A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid TumorsL & L Bio Co., Ltd., Ningbo, China · recruiting · Solid Tumor · principal investigator
- Ph2NCT06437509 · A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung CancerSichuan Baili Pharmaceutical Co., Ltd. · recruiting · Extensive-stage Small-cell Lung Cancer · principal investigator
- Ph1/Ph2NCT06306456 · A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLCSuzhou Genhouse Bio Co., Ltd. · recruiting · Non-Small Cell Lung Cancer With EGFR Mutation · principal investigator
- Ph1NCT06298058 · A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.Shanghai Institute Of Biological Products · recruiting · Advanced Solid Tumor · principal investigator
- Ph1NCT06132828 · Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid TumorsZhejiang Doer Biologics Co., Ltd. · recruiting · Solid Tumor · principal investigator
- Ph3NCT06080776 · SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR MutationsNanjing Sanhome Pharmaceutical, Co., Ltd. · recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT05994131 · IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLCInxMed (Shanghai) Co., Ltd. · recruiting · NSCLC · principal investigator
- Ph1/Ph2NCT05949619 · A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid TumorsSichuan Baili Pharmaceutical Co., Ltd. · active not recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT05949606 · A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerSichuan Baili Pharmaceutical Co., Ltd. · active not recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT05880706 · A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerSichuan Baili Pharmaceutical Co., Ltd. · active not recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph3NCT05673590 · Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerBeijing Biostar Pharmaceuticals Co., Ltd. · unknown · Locally Advanced or Metastatic Non-Small Cell Lung Cancer · principal investigator
- Ph3NCT05668988 · A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)Dizal Pharmaceuticals · active not recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT05519865 · A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLCChipscreen Biosciences, Ltd. · completed · Non Small Cell Lung Cancer · principal investigator
- Ph3NCT05487391 · A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.Qilu Pharmaceutical Co., Ltd. · recruiting · Carcinoma, Non-Small-Cell Lung · study chair
- Ph1NCT05370755 · A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid TumorsBeijing InnoCare Pharma Tech Co., Ltd. · unknown · Patients With Advanced Solid Tumors · principal investigator
- Ph1NCT05357651 · A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma(Keyplus-001)L & L Bio Co., Ltd., Ningbo, China · recruiting · Solid Tumor, Lymphoma · principal investigator
- Ph1/Ph2NCT05329298 · A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid TumorsBetta Pharmaceuticals Co., Ltd. · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT05223231 · Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant TumorsNanjing Leads Biolabs Co.,Ltd · completed · Advanced Malignant Tumors · principal investigator
- Ph2/Ph3NCT05001724 · KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 AgentJiangsu Alphamab Biopharmaceuticals Co., Ltd · terminated · Advanced Non-small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT04900363 · A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLCAkeso · completed · Non-small Cell Lung Cancer · principal investigator
- Ph3NCT04474119 · KN046 in Subjects With Advanced Squamous Non-small Cell Lung CancerJiangsu Alphamab Biopharmaceuticals Co., Ltd · unknown · Squamous Non-small-cell Lung Cancer · principal investigator
- N/ANCT04360655 · Bronchoscopic Microwave Intervention Treatment in Advanced Central NSCLCShanghai Pulmonary Hospital, Shanghai, China · unknown · Effect Increased, Safety Issues · principal investigator
- Ph2NCT04211922 · Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With CrizotinibSuzhou Zelgen Biopharmaceuticals Co.,Ltd · terminated · ALK-positive Non-small Cell Lung Cancer · study chair
- Ph2NCT03904823 · A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLCJiangsu HengRui Medicine Co., Ltd. · unknown · EGFR-mutant Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT03886441 · Prevention of Locally Advanced NSCLC Radiotherapy Pneumonia by Inhaling Beclomethasone PropionateTongji University · unknown · Locally Advanced Non Small Cell Lung Cancer · principal investigator
- Ph1NCT03852823 · Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced TumoursCSPC ZhongQi Pharmaceutical Technology Co., Ltd. · unknown · Advanced Solid Tumours, Cervical Cancer, Malignant Mesothelioma · principal investigator
- Ph2NCT03838848 · KN046 in Patients With Advanced Non-small Cell Lung CancerJiangsu Alphamab Biopharmaceuticals Co., Ltd · terminated · Stage IV Non-small Cell Lung Cancer · principal investigator
- Ph3NCT03668496 · A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLCJiangsu HengRui Medicine Co., Ltd. · unknown · Lung Cancer Squamous Cell, Lung Cancer Stage IV, PD-1 Antibody · principal investigator
- Ph3NCT03629925 · Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLCInnovent Biologics (Suzhou) Co. Ltd. · completed · Squamous NSCLC · principal investigator
- Ph3NCT03358875 · Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)BeiGene · completed · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT03267654 · Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation AbundanceQilu Pharmaceutical Co., Ltd. · unknown · Non-small-cell Lung Cancer · principal investigator
- Ph2NCT03002844 · EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion PolymorphismShanghai Pulmonary Hospital, Shanghai, China · unknown · Nonsmall Cell Lung Cancer, EGFR Gene Mutation · principal investigator
- Ph4NCT02996214 · Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU)Nanjing Luye Sike Pharmaceutical Co., Ltd. · unknown · Squamous Non-small-cell Lung Cancer · principal investigator
- N/ANCT02991274 · ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central LaboratoryAstraZeneca · completed · Locally Advanced or Metastatic EGFR(+) NSCLC Patients · principal investigator
- Ph2NCT02930954 · Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation AbundanceCaicun Zhou · unknown · Non-small-cell Lung Cancer · principal investigator
- Ph3NCT02859077 · EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion PolymorphismShanghai Pulmonary Hospital, Shanghai, China · unknown · Non-Small-Cell Lung Cancer · principal investigator
- Ph3NCT02766140 · SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung CancerJiangsu HengRui Medicine Co., Ltd. · terminated · Non Squamous Non Small Cell Lung · principal investigator
- N/ANCT02663492 · Transcutaneous Electrical Acupoint Stimulation for Non-small Cell Lung Cancer PatientsTongji University · unknown · Non-Small Cell Lung Cancer, Lung Cancer · principal investigator
- Ph2NCT02540824 · Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung CancerTongji University · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT02535507 · Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung CancerTongji University · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT02515435 · The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung CancerTongji University · unknown · Non-Small Cell Lung Cancer · principal investigator
- Ph3NCT02448797 · Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutationBetta Pharmaceuticals Co., Ltd. · unknown · Non-small Cell Lung Cancer · study chair
- Ph3NCT02058433 · Safety Study of Individual Paclitaxel Dose Adjustment Based on Pharmacokinetics in Non-Small Cell Lung Cancer (NSCLC)Caicun Zhou · unknown · Non-Small Cell Lung Cancer · principal investigator
- Ph3NCT01560195 · A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving ChemotherapyJiangsu HengRui Medicine Co., Ltd. · unknown · NSCLC, Neutropenia, Febrile Neutropenia · principal investigator
- Ph2NCT01424709 · Individualized Chemotherapy Based on BRCA1 and RRM1 mRNA for Advanced Non-small Cell Lung Cancer (NSCLC)Tongji University · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph3NCT00874419 · Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 MutationTongji University · completed · Non-small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 15:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 15:25 UTC. The ranking covers the 200 most relevant of 629 PubMed records, and a shared surname and initials can bring in a namesake. All 629 on PubMed
- Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.N Engl J Med · 20184,615 citationsRCR 168.8
- 3,498 citationsRCR 88.2
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.N Engl J Med · 20202,543 citationsRCR 114.6
- 1,319 citationsRCR 72.2
- 1,313 citationsRCR 39.5
- 862 citationsRCR 23.0
- 408 citationsRCR 19.3
- 406 citationsRCR 24.7
- 391 citationsRCR 10.4
- Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.N Engl J Med · 2023368 citationsRCR 29.4